When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Women with a finding of atypical glandular cells (AGC) on cervical cytology are more likely than those without AGC to have malignant breast…
NEW YORK (Reuters Health) – After induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia (CLL), consolidation therapy with the monoclonal anti-CD52 antibody alemtuzumab (Campath-1H) improved…
NEW YORK (Reuters Health) – Concerns that bisphosphonate drugs used to treat osteoporosis might increase the risk of developing esophageal cancer have been put to rest by a…
NEW YORK (Reuters Health) – Patients who have undergone prior systemic therapies for cutaneous T-cell lymphoma may respond well to treatment with romidepsin, a potent inhibitor of histone…
NEW YORK (Reuters Health) – For selected patients with locally advanced or metastatic non-small-cell lung cancer, a split course of radiation given over a short period works well…
NEW YORK (Reuters Health) – Patients with localized prostate cancer can be treated successfully with high-intensity focused ultrasound (HIFU), with results comparable to those expected with external-beam radiation…
NEW YORK (Reuters Health) – On a matched-pair analysis, the results of decompressive surgery followed by radiotherapy for metastatic spinal cord compression were seen to be similar to…
NEW YORK (Reuters Health) – Results of primary percutaneous intervention (PCI) in patients with ST-segment elevation MI are better when the procedure is performed via the radial artery…
NEW YORK (Reuters Health) – Updated guidelines issued by the American Society of Clinical Oncology (ASCO) recommend that postmenopausal women with hormone receptor-positive breast cancer should receive aromatase…
NEW YORK (Reuters Health) – First-line therapy with zidovudine and interferon-alpha improves overall survival in patients with adult T-cell leukemia/lymphoma (ATL), according to the results of a retrospective…
